For inoperable advanced NSCLC patients with the epidermal growth factor receptor (EGFR) sensitive mutation, EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have been recommended as the first line choice (2–5). Here, EGFR is linked to non-small cell lung carcinoma.